Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 8/20 | 0.44 |
| ▸ | JAK3 | P52333 | 8/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 7/20 | 0.44 |
| ▸ | IGF1R | P08069 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 4/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12671571 | 0.87 | IGF1R (0.40) | JAK2JAK3PTK2IGF1REGFR | |
| SCHEMBL1570314 | 0.87 | IKBKB (0.45) | JAK2JAK3PTK2IGF1REGFR | |
| SCHEMBL1572268 | 0.87 | IGF1R (0.43) | JAK2JAK3PTK2IGF1REGFR | |
| SCHEMBL1570949 | 0.87 | TBK1 (0.46) | JAK2JAK3IGF1REGFRJAK1 | |
| SCHEMBL1572127 | 0.86 | EGFR (0.46) | JAK2JAK3IGF1REGFRJAK1 | |
| SCHEMBL1633896 | 0.85 | TBK1 (0.48) | JAK2IGF1REGFRLRRK2 | |
| SCHEMBL1872243 | 0.85 | GPR119 (0.44) | JAK2JAK3PTK2IGF1REGFR | |
| SCHEMBL1571689 | 0.84 | EGFR (0.51) | JAK2JAK3IGF1REGFRJAK1 | |
| SCHEMBL3320675 | 0.81 | CHEK2 (0.47) | JAK2JAK3IGF1RIKBKBPDE4B | |
| SCHEMBL12671180 | 0.81 | JAK3 (0.51) | JAK2JAK3PTK2IGF1RALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| WO-2009153313-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | JAK2 1056/4885JAK3 1979/4885PTK2 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.